Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997201 | 1.00 | ODC1 (0.48) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL997202 | 1.00 | ODC1 (0.48) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL2392881 | 0.79 | LMNA (0.44) | LMNABLMPMP22THRBKMT2A | |
| SCHEMBL10912285 | 0.77 | ODC1 (0.42) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL4727982 | 0.76 | ODC1 (0.43) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL2886844 | 0.74 | ODC1 (0.40) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL29116696 | 0.72 | ODC1 (0.56) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL6632838 | 0.72 | ODC1 (0.56) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL11436674 | 0.71 | ODC1 (0.60) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL162369 | 0.68 | ARG1 (0.59) | ODC1LMNABLMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| EP-1373185-B1 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | AMINEX THERAPEUTICS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| WO-2007082822-A1 | NOVEL USE OF A POLYAMINE-DEPLETED FOOD COMPOSITION FOR HUMAN OR VETERINARY USE, FOR PREPARING A THERAPEUTIC FOOD PRODUCT | UNIVERSITE DE RENNES 1 (FR) | 2007-07-26 | — | — | WO | disclosed |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| CN-1511137-A | Hydrophobic polyamine analogs and methods of use thereof | 麦迪凯斯特治疗学股份有限公司 | 2004-07-07 | — | — | CN | disclosed |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. | 2003-10-02 | — | — | US | disclosed |
| EP-0703731-B1 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT, AND THERAPEUTICAL USES THEREOF | UNIV RENNES (FR) | 1998-04-08 | — | — | EP | disclosed |
| EP-0703732-B1 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT | UNIV RENNES (FR) | 1997-09-17 | — | — | EP | disclosed |
| EP-0703731-A1 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT, AND THERAPEUTICAL USES THEREOF | UNIVERSITE DE RENNES I (FR) | 1996-04-03 | — | — | EP | disclosed |
| EP-0703732-A1 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT | UNIV RENNES (FR) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995000041-A1 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT, AND THERAPEUTICAL USES THEREOF | UNIVERSITE DE RENNES 1 (FR) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000042-A2 | FOOD AND/OR PHARMACEUTICAL COMPOSITION HAVING A LOW POLYAMINE CONTENT | UNIVERSITE DE RENNES 1 (FR) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | ODC1 13/4885LMNA 1571/4885BLM 2402/4885 |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | ODC1 8/4885LMNA 1715/4885BLM 1571/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | ODC1 8/4885LMNA 1715/4885BLM 1571/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | ODC1 29/4885LMNA 2156/4885BLM 2975/4885 |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | SLC7A1, SRM, SLC16A1 | ODC1 15/4885LMNA 2140/4885BLM 3097/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | ODC1 788/4885LMNA 2354/4885BLM 499/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | ODC1 788/4885LMNA 2354/4885BLM 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.